Agents targeting c-Jun N-terminal kinase pathway as potential neuroprotectants

Expert Opinion on Investigational Drugs

Volumn 14, Issue 11, 2005, Pages 1373-1383

  Zhang, Guang Yi ^a   Zhang, Quan Guang ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Agents; c Jun N terminal kinase; Mixed lineage kinase; Neuroprotection

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 1,3 BENZOTHIAZOL 2 YL [2 [[2 (3 PYRIDINYL)ETHYL]AMINO] 4 PYRIMIDINYL]ACETONITRILE; ACETONITRILE DERIVATIVE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTISENSE OLIGONUCLEOTIDE; AS 601245; CEP 11004; CEP 1347; K 252A; K 252B; KTD 606; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; PEPTIDE DERIVATIVE; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; CELL LINE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC INFLAMMATION; CLINICAL TRIAL; DATA ANALYSIS; DEGENERATIVE DISEASE; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GENE INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUNTINGTON CHOREA; IC 50; MEDICAL RESEARCH; MITOCHONDRION; NERVE CELL NECROSIS; NERVE CELL STIMULATION; NEUROMODULATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION;

ACETONITRILES; ANIMALS; ANTHRACENES; APOPTOSIS; BENZOTHIAZOLES; CARBAZOLES; HUMANS; INDOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NEUROPROTECTIVE AGENTS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; THIAZOLES;

EID: 27744468983     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.11.1373     Document Type: Review

References (122)

1. CHANG L, KARIN M: Mammalian MAP kinase signalling cascades. Nature (2001) 410(6824):37-40.
2. ICHIJO H: From receptors to stress-activated MAP kinases. Oncogene (1999) 18(45):6087-6093.
3. IRVING EA, BAMFORD M: Role of mitogen- and stress-activated kinases in ischemic injury. J. Cereb. Blood Flow Metab. (2002) 22(6):631-647.
4. KYRIAKIS JM, AVRUCH J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. (2001) 81(2):807-869.
5. DAVIS RJ: Signal transduction by the JNK group of MAP kinases. Cell (2000) 103(2):239-252.
6. 2-terminal kinase. Proc. Natl. Acad. Sci. USA (1997) 94(14):7337-7342.
7. ICHIJO H, NISHIDA E, IRIE K et al.: Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science (1997) 275(5296):90-94.
8. KYRIAKIS JM, AVRUCH J: Protein kinase cascades activated by stress and inflammatory cytokines. Bioessays (1996) 18(7):567-577.
9. TIBBLES LA, ING YL, KIEFER F et al.: MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6. Embo J. (1996) 15(24):7026-7035.
10. MINDEN A, LIN A, McMAHON M et al.: Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science (1994) 266(5191):1719-1723.
11. YAMAGUCHI K, SHIRAKABE K, SHIBUYA H et al.: Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science (1995) 270(5244):2008-2011.
12. PAWSON T, SCOTT JD: Signaling through scaffold, anchoring, and adaptor proteins. Science (1997) 278(5346):2075-2080.
13. YASUDA J, WHITMARSH AJ, CAVANAGH J, SHARMA M, DAVIS RJ: The JIP group of mitogen-activated protein kinase scaffold proteins. Mol. Cell. Biol. (1999) 19(10):7245-7254.
14. HARDING TC, XUE L, BIENEMANN A et al.: Inhibition of JNK by overexpression of the JNL binding domain of JIP-1 prevents apoptosis in sympathetic neurons. J. Biol. Chem. (2001) 276(7):4531-4534.
15. McDONALD PH, CHOW CW, MILLER WE et al.: β-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science (2000) 290(5496):1574-1577.
16. TAPON N, NAGATA K, LAMARCHE N, HALL A: A new rac target POSH is an SH3-containing scaffold protein involved in the JNK and NF-κB signalling pathways. Embo J. (1998) 17(5):1395-1404.
17. XU Z, KUKEKOV NV, GREENE LA: POSH acts as a scaffold for a multiprotein complex that mediates JNK activation in apoptosis. Embo J. (2003) 22(2):252-261.
18. KUAN CY, YANG DD, SAMANTA ROY DR et al.: The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron (1999) 22(4):667-676.
19. XIA Z, DICKENS M, RAINGEAUD J, DAVIS RJ, GREENBERG ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science (1995) 270(5240):1326-1331.
20. YANG DD, KUAN CY, WHITMARSH AJ et al.: Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature (1997) 389(6653):865-870.
21. BRUCKNER SR, TAMMARIELLO SP, KUAN CY et al.: JNK3 contributes to c-Jun activation and apoptosis but not oxidative stress in nerve growth factor-deprived sympathetic neurons. J. Neurochem. (2001) 78(2):298-303.
22. SABAPATHY K, JOCHUM W, HOCHEDLINGER K et al.: Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2. Mech. Dev. (1999) 89(1-2):115-124.
23. BEHRENS A, SIBILIA M, WAGNER EF: Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat. Genet. (1999) 21(3):326-329.
24. WHITMARSH AJ, KUAN CY, KENNEDY NJ et al.: Requirement of the JIP1 scaffold protein for stress-induced JNK activation. Genes Dev. (2001) 15(18):2421-2432.
25. IM JY, LEE KW, KIM MH et al.: Repression of phospho-JNK and infarct volume in ischemic brain of JIP1-deficient mice. J. Neurosci. Res. (2003) 74(2):326-332.
26. SANCHEZ I, YUAN J: A convoluted way to die. Neuron (2001) 29(3):563-566.
27. LEI K, DAVIS RJ: JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc. Natl. Acad. Sci. USA (2003) 100(5):2432-2437.
28. BOZYCZKO-COYNE D, O'KANE TM, WU ZL et al.: CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Aβ-induced cortical neuron apoptosis. J. Neurochem. (2001) 77(3):849-863.
29. HARRIS CA, JOHNSON EM Jr: BH3-only Bcl-2 family members are coordinately regulated by the JNK pathway and require Bax to induce apoptosis in neurons. J. Biol. Chem. (2001) 276(41):37754-37760.
30. WHITFIELD J, NEAME SJ, PAQUET L, BERNARD O, HAM J: Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron (2001) 29(3):629-643.
31. LE-NICULESCU H, BONFOCO E, KASUYA Y et al.: Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol. Cell. Biol. (1999) 19(1):751-763.
32. SCHULZE-OSTHOFF K, FERRARI D, LOS M, WESSELBORG S, PETER ME: Apoptosis signaling by death receptors. Eur. J. Biochem. (1998) 254(3):439-459.
33. WATSON A, EILERS A, LALLEMAND D et al.: Phosphorylation of c-Jun is necessary for apoptosis induced by survival signal withdrawal in cerebellar granule neurons. J. Neurosci. (1998) 18(2):751-762.
34. ADLER V, PINCUS MR, MINAMOTO T et al.: Conformation-dependent phosphorylation of p53. Proc. Natl. Acad. Sci. USA (1997) 94(5):1686-1691.
35. KYRIAKIS JM, AVPUCH J: Sounding the alarm: protein kinase cascades activated by stress and inflammation. J. Biol. Chem. (1996) 271(40):24313-24316.
36. DENG T, KARIN M: JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers. Genes Dev. (1993) 7(3):479-490.
37. GUPTA S, CAMPBELL D, DERIJARD B, DAVIS RJ: Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science (1995) 267(5196):389-393.
38. TSURUTA F, SUNAYAMA J, MORI Y et al.: JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. Embo J. (2004) 23(8):1889-1899.
39. CHANG LK, PUTCHA GV, DESHMUKH M, JOHNSON EM Jr: Mitochondrial involvement in the point of no return in neuronal apoptosis. Biochimie (2002) 84(2-3):223-231.
40. WANG X: The expanding role of mitochondria in apoptosis. Genes Dev. (2001) 15(22):2922-2933.
41. CAIN K: Chemical-induced apoptosis: formation of the Apaf-1 apoptosome. Drug Metab. Rev. (2003) 35(4):337-363.
42. CHEN J, NAGAYAMA T, JIN K et al.: Induction of caspase-3-like protease may mediate delayed neuronal death in the hippocampus after transient cerebral ischemia. J. Neurosci. (1998) 18(13):4914-4928.
43. DLUZNIEWSKA J, BERESEWICZ M, WOJEWODZKA U, GAJKOWSKA B, ZABLOCKA B: Transient cerebral ischemia induces delayed proapoptotic Bad translocation to mitochondria in CA1 sector of hippocampus. Brain Res. Mol. Brain Res. (2005) 133(2):274-280.
44. MULLER GJ, STADELMANN C, BASTHOLM L et al.: Ischemia leads to apoptosis-and necrosis-like neuron death in the ischemic rat hippocampus. Brain Pathol. (2004) 14(4):415-424.
45. TOURNIER C, HESS P, YANG DD et al.: Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science (2000) 288(5467):870-874.
46. FAN M, DU L, STONE AA, GILBERT KM, CHAMBERS TC: Modulation of mitogen-activated protein kinases and phosphorylation of Bcl-2 by vinblastine represent persistent forms of normal fluctuations at G2-M1. Cancer Res. (2000) 60(22):6403-6407.
47. MIELKE K, HERDEGEN T: JNK and p38 stress kinases-degenerative effectors of signal-transduction-cascades in the nervous system. Prog. Neurobiol. (2000) 61(1):45-60.
48. SCHROETER H, BOYD CS, AHMED R et al.: c-Jun N-terminal kinase (JNK)-mediated modulation of brain mitochondria function: new target proteins for JNK signalling in mitochondrion-dependent apoptosis. Biochem. J. (2003) 372(Part 2):359-369.
49. CHAUHAN D, LI G, HIDESHIMA T et al.: JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J. Biol. Chem. (2003) 278(20):17593-17596.
50. HARADA H, GRANT S: Apoptosis regulators. Rev. Clin. Exp. Hematol. (2003) 7(2):117-138.
51. 2+-pcrmeable alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors involving oxidative stress following brain ischemia in rat hippocampus. Neurosci. Lett. (2003) 337(1):51-55.
52. ZHANG Q, ZHANG G: Activation and autophosphorylation of apoptosis signal-regulating kinase 1 (ASK1) following cerebral ischemia in rat hippocampus. Neurosci. Lett. (2002) 329(2):232-236.
53. TIAN H, ZHANG Q, LI H, ZHANG G: Antioxidant N-acetylcysteine and AMPA/KA receptor antagonist DNQX inhibited mixed lineage kinase-3 activation following cerebral ischemia in rat hippocampus. Neurosci. Res. (2003) 47(1):47-53.
54. PEI DS, SUN YF, GUAN QH et al.: Postsynaptic density protein 95 antisense oligodeoxynucleotides inhibits the activation of MLK3 and JNK3 via the GluR6.PSD-95.MLK3 signaling module after transient cerebral ischemia in rat hippocampus. Neurosci. Lett. (2004) 367(1):71-75.
55. MIAO B, YIN XH, PEI DS, ZHANG QG, ZHANG GY: Neuroprotective effects of preconditioning ischemia on ischemic brain injury through down-regulating activation of JNK1/2 via N-methyl-D-aspartate receptor-mediated Akt1 activation. J. Biol. Chem. (2005) 280(23):21693-21699.
56. YIN XH, ZHANG QG, MIAO B, ZHANG GY: Neuroprotective effects of preconditioning ischaemia on ischaemic brain injury through inhibition of mixed-lineage kinase 3 via NMDA receptor-mediated Akt1 activation. J. Neurochem. (2005) 93(4):1021-1029.
57. GU Z, JIANG Q, ZHANG G: Extracellular signal-regulated kinase and c-Jun N-terminal protein kinase in ischemic tolerance. Neuroreport (2001) 12(16):3487-3491.
58. GU Z, JIANG Q, ZHANG G: c-Jun N-terminal kinase activation in hippocampal CA1 region was involved in ischemic injury. Neuroreport (2001) 12(5):897-900.
59. BERG MM, STERNBERG DW, PARADA LF, CHAO MV: K-252a inhibits nerve growth factor-induced trk proto-oncogene tyrosine phosphorylation and kinase activity. J. Biol. Chem. (1992) 267(1):13-16.
60. KANEKO M, SAITO Y, SAITO H et al.: Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives. J. Med. Chem. (1997) 40(12):1863-1869.
61. GINGRICH DE, YANG SX, GESSNER GW, ANGELES TS, HUDKINS RL: Synthesis, modeling, and in vitro activity of (3′S)-epi-K-252a analogues. Elucidating the stereochemical requirements of the 3′-sugar alcohol on trkA tyrosine kinase activity. J. Med. Chem. (2005) 48(11):3776-3783.
62. BORASIO GD: Differential effects of the protein kinase inhibitor K-252a on the in vitro survival of chick embryonic neurons. Neurosci. Lett. (1990) 108(1-2):207-212.
63. HASHIMOTO S, HAGINO A: Staurosporine-induced neurite outgrowth in PC12h cells. Exp. Cell Res. (1989) 184(2):351-359.
64. GLICKSMAN MA, PRANTNER JE, MEYER SL et al.: K-252a and staurosporine promote choline acetyltransferase activity in rat spinal cord cultures. J. Neurochem. (1993) 61(1):210-221.
65. GLICKSMAN MA, FORBES ME, PRANTNER JE, NEFF NT: K-252a promotes survival and choline acetyltransferase activity in striatal and basal forebrain neuronal cultures. J. Neurochem. (1995) 64(4):1502-1512.
66. ROUX PP, DORVAL G, BOUDREAU M et al.: K252a and CEP1347 are neuroprotective compounds that inhibit mixed-lineage kinase-3 and induce activation of Akt and ERK. J. Biol. Chem. (2002) 277(51):49473-49480.
67. KNUSEL B, HEFTI F: K-252 compounds: modulators of neurotrophin signal transduction. J. Neurochem. (1992) 59(6):1987-1996.
68. KNUSEL B, KAPLAN DR, WINSLOW JW et al.: K-252b selectively potentiates cellular actions and trk tyrosine phosphorylation mediated by neurotrophin-3. J. Neurochem. (1992) 59(2):715-722.
69. MARONEY AC, GLICKSMAN MA, BASMA AN et al.: Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J. Neurosci. (1998) 18(1):104-111.
70. ANGELES TS, YANG SX, STEFFLER C, DIONNE CA: Kinetics of trkA tyrosine kinase activity and inhibition by K-252a. Arch. Biochem. Biophys. (1998) 349(2):267-274.
71. SAPORITO MS, HUDKINS RL, MARONEY AC: Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. Prog. Med. Chem. (2002) 40:23-62.
72. MARONEY AC, FINN JP, BOZYCZKO-COYNE D et al.: CEP-1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by three distinct insults. J. Neurochem. (1999) 73(5):1901-1912.
73. MARONEY AC, FINN JP, CONNORS TJ et al.: Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J. Biol. Chem. (2001) 276(27):25302-25308.
74. HARRIS CA, DESHMUKH M, TSUI-PIERCHALA B, MARONEY AC, JOHNSON EM Jr: Inhibition of the c-Jun N-terminal kinase signaling pathway by the mixed lineage kinase inhibitor CEP-1347 (KT7515) preserves metabolism and growth of trophic factor-deprived neurons. J. Neurosci. (2002) 22(1):103-113.
75. BORASIO GD, HORSTMANN S, ANNESER JM, NEFF NT, GLICKSMAN MA: CEP-1347/KT7515, a JNK pathway inhibitor, supports the in vitro survival of chick embryonic neurons. Neuroreport (1998) 9(7):1435-1439.
76. MARONEY AC, LIPFERT L, FORBES ME et al.: K-252a induces tyrosine phosphorylation of the focal adhesion kinase and neurite outgrowth in human neuroblastoma SH-SY5Y cells. J. Neurochem. (1995) 64(2):540-549.
77. BOZYCZKO-COYNE D, SAPORITO MS, HUDKINS RL: Targeting the JNK pathway for therapeutic benefit in CNS disease. Curr. Drug Targets CNS Neurol. Disord. (2002) 1(1):31-49.
78. RESNICK L, FENNELL M: Targeting JNK3 for the treatment of neurodegenerative disorders. Drug Discov. Today (2004) 9(21):932-939.
79. MANNING AM, DAVIS RJ: Targeting JNK for therapeutic benefit: from junk to gold? Nat. Rev. Drug Discov. (2003) 2(7):554-565.
80. WANG LH, BESIRLI CG, JOHNSON EM Jr: Mixed-lineage kinases: a target for the prevention of neurodegeneration. Ann. Rev. Pharmacol. Toxicol. (2004) 44:451-474.
81. SAPORITO MS, THOMAS BA, SCOTT RW: MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J. Neurochem. (2000) 75(3):1200-1208.
82. SAPORITO MS, BROWN EM, MILLER MS, CARSWELL S: CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J. Pharmacol. Exp. Ther. (1999) 288(2):421-427.
83. SILVA RM, KUAN CY, RAKIC P, BURKE RE: Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: a new therapeutic target in Parkinson's disease. Mov. Disord. (2005) 20(6):653-664.
84. PAN J, ZHANG QG, ZHANG GY: The neuroprotective effects of K252a through inhibiting MLK3/MKK7/JNK3 signaling pathway on ischemic brain injury in rat hippocampal CA1 region. Neuroscience (2005) 131(1):147-159.
85. HAN Z, BOYLE DL, CHANG L et al.: c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest. (2001) 108(1):73-81.
86. BENNETT BL, SASAKI DT, MURRAY BW et al.: SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA (2001) 98(24):13681-13686.
87. WANG W, MA C, MAO Z, LI M: JNK inhibition as a potential strategy in treating Parkinson's disease. Drug News Perspect. (2004) 17(10):646-654.
88. BOGOYEVITCH MA, BOEHM I, OAKLEY A, KETTERMAN AJ, BARR RK: Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim. Biophys. Acta (2004) 1697(1-2):89-101.
89. BAIN J, McLAUCHLAN H, ELLIOTT M, COHEN P: The specificities of protein kinase inhibitors: an update. Biochem. J. (2003) 371(Part 1):199-204.
90. GUAN QH, PEI DS, ZHANG QG et al.: The neuroprotective action of SP600125, a new inhibitor of JNK, on transient brain ischemia/reperfusion-induced neuronal death in rat hippocampal CA1 via nuclear and non-nuclear pathways. Brain Res. (2005) 1035(1):51-59.
91. GAO Y, SIGNORE AP, YIN W et al.: Neuroprotection against focal ischemic brain injury by inhibition of c-Jun N-terminal kinase and attenuation of the mitochondrial apoptosis-signaling pathway. J. Cereb. Blood Flow Metab. (2005) 25(6):694-712.
92. WANG W, SHI L, XIE Y et al.: SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease. Neurosci. Res. (2004) 48(2):195-202.
93. 2-terminal protein kinase inhibitor with neuroprotective properties. J. Pharmacol. Exp. Ther. (2004) 310(1):25-32.
94. FERRANDI C, BALLERIO R, GAILLARD P et al.: Inhibition of c-Jun N-terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats. Br. J. Pharmacol. (2004) 142(6):953-960.
95. CARBONI S, ANTONSSON B, GAILLARD P et al.: Control of death receptor and mitochondrial-dependent apoptosis by c-Jun N-terminal kinase in hippocampal CA1 neurones following global transient ischaemia. J. Neurochem. (2005) 92(5):1054-1060.
96. WHITMARSH AJ, CAVANAGH J, TOURNIER C, YASUDA J, DAVIS RJ: A mammalian scaffold complex that selectively mediates MAP kinase activation. Science (1998) 281(5383):1671-1674.
97. LEVCHENKO A, BRUCK J, STERNBERG PW: Scaffold proteins may biphasically affect the levels of mitogen-activated protein kinase signaling and reduce its threshold properties. Proc. Natl. Acad. Sci. USA (2000) 97(11):5818-5823.
98. BARR RK, KENDRICK TS, BOGOYEVITCH MA: Identification of the critical features of a small peptide inhibitor of JNK activity. J. Biol. Chem. (2002) 277(13):10987-10997.
99. SCHWARZE SR, HO A, VOCERO-AKBANI A, DOWDY SF: In vivo protein transduction: delivery of a biologically active protein into the mouse. Science (1999) 285(5433):1569-1572.
100. JOLIOT A, PROCHIANTZ A: Transduction peptides: from technology to physiology. Nat. Cell Biol. (2004) 6(3):189-196.
101. BORSELLO T, CLARKE PG, HIRT L et al.: A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. (2003) 9(9):1180-1186.
102. HIRT L, BADAUT J, THEVENET J et al.: D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia. Stroke (2004) 35(7):1738-1743.
103. WANG J, VAN DE WATER TR, BONNY C et al.: A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J. Neurosci. (2003) 23(24):8596-8607.
104. BONNY C, OBERSON A, NEGRI S, SAUSER C, SCHORDERET DF: Cell-permeable peptide inhibitors of JNK: novel blockers of β-cell death. Diabetes (2001) 50(1):77-82.
105. NAWROT B: Targeting BACE with small inhibitory nucleic acids - a future for Alzheimer's disease therapy? Acta Biochim. Pol. (2004) 51(2):431-444.
106. GOLDEN T, DEAN NM, HONKANEN RE: Use of antisense oligonucleotides: advantages, controls, and cardiovascular tissue. Microcirculation (2002) 9(1):51-64.
107. WEISS B, DAVIDKOVA G, ZHANG SP: Antisense strategies in neurobiology. Neurochem. Int. (1997) 31(3):321-348.
108. PROBST JC: Antisense oligodeoxynucleotide and ribozyme design. Methods (2000) 22(3):271-281.
109. ZANKE BW, BOUDREAU K, RUBIE E et al.: The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat. Curr. Biol. (1996) 6(5):606-613.
110. VERHEIJ M, BOSE R, LIN XH et al.: Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature (1996) 380(6569):75-79.
111. CHEN YR, WANG X, TEMPLETON D, DAVIS RJ, TAN TH: The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J. Biol. Chem. (1996) 271(50):31929-31936.
112. PETERSON TC, PETERSON MR, ROBERTSON HA, DURING M, DRAGUNOW M: Selective down-regulation of c-jun gene expression by pentoxifylline and c-jun antisense interrupts platelet-derived growth factor signaling: pentoxifylline inhibits phosphorylation of c-Jun on serine 73. Mol. Pharmacol. (2002) 61(6):1476-1488.
113. KIM SD, MOON CK, EUN SY, RYU PD, JO SA: Identification of ASK1, MKK4, JNK, c-Jun, and caspase-3 as a signaling cascade involved in cadmium-induced neuronal cell apoptosis. Biochem. Biophys. Res. Commun. (2005) 328(1):326-334.
114. 2-terminal kinase-mediated neurotoxic signal via dimerization. J. Pharmacol. Exp. Ther. (2003) 306(3):889-902.
115. YOSHIZUMI M, ABE J, TSUCHIYA K, BERK BC, TAMAKI T: Stress and vascular responses: atheroprotective effect of laminar fluid shear stress in endothelial cells: possible role of mitogen-activated protein kinases. J. Pharmacol. Sci. (2003) 91(3):172-176.
116. WAETZIG V, HERDEGEN T: A single c-Jun N-terminal kinase isoform (JNK3-p54) is an effector in both neuronal differentiation and cell death. J. Biol. Chem. (2003) 278(1):567-572.
117. CHANG L, JONES Y, ELLISMAN MH, GOLDSTEIN LS, KARIN M: JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins. Dev. Cell (2003) 4(4):521-533.
118. COFFEY ET, HONGISTO V, DICKENS M, DAVIS RJ, COURTNEY MJ: Dual roles for c-Jun N-terminal kinase in developmental and stress responses in cerebellar granule neurons. J. Neurosci. (2000) 20(20):7602-7613.
119. COFFEY ET, SMICIENE G, HONGISTO V et al.: c-Jun N-terminal protein kinase (JNK) 2/3 is specifically activated by stress, mediating c-Jun activation, in the presence of constitutive JNK1 activity in cerebellar neurons. J. Neurosci. (2002) 22(11):4335-4345.
120. KENNEDY NJ, SLUSS HK, JONES SN et al.: Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes Dev. (2003) 17(5):629-637.
121. RAIVICH G, BOHATSCHEK M, DA COSTA C et al.: The AP-1 transcription factor c-Jun is required for efficient axonal regeneration. Neuron (2004) 43(1):57-67.
122. ENGELBERG D: Stress-activated protein kinases-tumor suppressors or tumor initiators? Semin. Cancer Biol. (2004) 14(4):271-282.